Hospital
Christus Health Southwestern Louisiana
Christus Health Southwestern Louisiana was paid $10.18M by Medicaid between Jan 2018 and Dec 2024, across 84 billing codes. Its largest line is 99284, emergency room visit (serious) — 32% of everything it billed.
33Billing provider infoCHRISTUS HEALTH SOUTHWESTERN LOUISIANA
LAKE CHARLES, LA 70601
LAKE CHARLES, LA 70601
33aNPI1629076468assigned 07/13/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.18M
24GClaims293,011
24DCodes billed84
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#35 of 96
Median peer was paid$5.17M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TREVINO, PAUL controls 11+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,813 | $942K | |
| 2019 | 37,753 | $852K | |
| 2020 | 35,488 | $860K | |
| 2021 | 43,904 | $1.41M | |
| 2022 | 55,584 | $2.13M | |
| 2023 | 49,124 | $2.17M | |
| 2024incomplete | 34,345 | $1.81M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 32% | 19,029 | 17,128 | $3.27M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 10,948 | 9,717 | $2.14M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 18,260 | 16,771 | $1.53M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 5.7% | 15,697 | 13,375 | $580K |
| 71045 | Radiologic examination, chest; single view | 2.8% | 12,168 | 10,863 | $287K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.5% | 2,019 | 1,777 | $254K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.4% | 5,369 | 4,694 | $240K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 527 | 460 | $236K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 738 | 672 | $208K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.5% | 4,249 | 3,803 | $149K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.4% | 583 | 513 | $146K |
| 80053 | Comprehensive metabolic panel | 1.4% | 21,761 | 19,253 | $144K |
72 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 22,762 | $109K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,247 | $90K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 24,610 | $80K |
| 84484 | <1% | 9,158 | $65K | |
| 83880 | <1% | 2,749 | $57K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 801 | $57K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 174 | $56K |
| 36415 | Collection of venous blood by venipuncture | <1% | 28,334 | $50K |
| 81025 | <1% | 6,764 | $42K | |
| 84145 | <1% | 2,606 | $40K | |
| 80050 | General health panel | <1% | 1,023 | $38K |
| 81001 | <1% | 16,846 | $32K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,903 | $29K |
| 83605 | <1% | 4,110 | $27K | |
| 83690 | <1% | 5,200 | $24K | |
| 85730 | <1% | 6,642 | $22K | |
| 82077 | <1% | 2,430 | $21K | |
| 85610 | <1% | 7,067 | $17K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 409 | $13K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,750 | $10K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 363 | $9K |
| 82550 | <1% | 2,174 | $9K | |
| 85379 | <1% | 1,176 | $8K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 266 | $8K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,231 | $7K |
| 83735 | <1% | 1,514 | $6K | |
| 86328 | <1% | 490 | $6K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $6K |
| 80061 | Lipid panel | <1% | 470 | $5K |
| 80143 | <1% | 467 | $5K | |
| 80179 | <1% | 441 | $5K | |
| 82553 | <1% | 730 | $4K | |
| 87040 | <1% | 720 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 962 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 421 | $3K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 117 | $3K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 779 | $3K |
| 84439 | <1% | 355 | $3K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,898 | $2K |
| G0378 | Hospital observation service, per hour | <1% | 22 | $2K |
| 80320 | <1% | 422 | $2K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 5,962 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 48 | $1K |
| 86592 | <1% | 293 | $879.10 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 206 | $871.39 |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 101 | $603.23 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 110 | $443.35 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12 | $370.22 |
| 69990 | <1% | 57 | $337.41 | |
| 81003 | <1% | 242 | $294.21 | |
| 84703 | <1% | 46 | $264.14 | |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 3,871 | $214.64 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12 | $184.97 |
| 86140 | <1% | 40 | $171.61 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 109 | $156.83 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 154 | $136.07 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 29 | $110.39 |
| 94760 | <1% | 193 | $103.22 | |
| 80076 | <1% | 13 | $98.12 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 43 | $40.49 |
| 82962 | <1% | 19 | $39.62 | |
| A6402 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | <1% | 148 | $27.33 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 27 | $23.92 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 78 | $13.11 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 66 | $9.13 |
| A9270 | Non-covered item or service | <1% | 603 | $0.46 |
| 80329 | 0% | 81 | $0.00 | |
| 00000 | 0% | 65 | $0.00 | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 51 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 50 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 138 | $0.00 |
| 90853 | Group psychotherapy (other than of a multiple-family group) | 0% | 180 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTREVINO, PAUL (CEO)
| Provider | Location | Paid |
|---|---|---|
| Christus Health Southeast Texas | Beaumont, TX | $21.00M |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $11.89M |
| Christus Health Southeast Texas | Jasper, TX | $5.51M |
| Christus Health Southeast Texas | Jasper, TX | $699K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $223K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $145K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $136K |
| Christus Health Southwestern Louisiana | Grand Chenier, LA | $113K |
| Christus Health Southeast Texas | Kirbyville, TX | $86K |
| Christus Health Southwestern Louisiana | Lake Charles, LA | $41K |
| Christus Health Southeast Texas | Beaumont, TX | $175.14 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.